Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PETHEMA LAL-2019
- Development stage
- Unknown
- Lead developer
- Fundación PETHEMA
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral, Intramuscular, Intrathecal
01
Overview
PETHEMA LAL-2019 is a pediatric-inspired, risk-adapted chemotherapy regimen developed by the PETHEMA Foundation for adult patients with Philadelphia chromosome-negative (Ph-negative) acute lymphoblastic leukemia (ALL). The protocol, currently under investigation in a multicenter Phase 3 trial (NCT04179929), utilizes a multi-phase approach consisting of induction, early and delayed consolidation, reinduction, and maintenance. Treatment intensity is tailored based on measurable residual disease (MRD) levels and baseline genetic risk factors. Patients achieving early MRD clearance with standard genetic risk continue with chemotherapy blocks, while high-risk patients or those with persistent MRD are allocated to allogeneic hematopoietic stem cell transplantation (alloHSCT). The regimen incorporates a combination of cytotoxic agents including vincristine, prednisone, pegaspargase, daunorubicin, methotrexate, cytarabine, and mercaptopurine.
- Other names
- PETHEMA LAL19 protocolPETHEMA LAL-2019 chemotherapy protocol
02
Targets
PPAT (Amidophosphoribosyltransferase)DNADNA polymerase familyTOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on PETHEMA LAL-2019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PETHEMA LAL-2019.